CR10212A - Modulacion de la formacion osea - Google Patents

Modulacion de la formacion osea

Info

Publication number
CR10212A
CR10212A CR10212A CR10212A CR10212A CR 10212 A CR10212 A CR 10212A CR 10212 A CR10212 A CR 10212A CR 10212 A CR10212 A CR 10212A CR 10212 A CR10212 A CR 10212A
Authority
CR
Costa Rica
Prior art keywords
ror2
osea
training
modulation
bone
Prior art date
Application number
CR10212A
Other languages
English (en)
Inventor
Julia Billiard
Yan Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10212A publication Critical patent/CR10212A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/108Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención se relaciona con modular actividad Ror (por ejemplo, actividad de la proteína Ror2) o 14-3-3 B para afectar la formación o la resorción ósea. La invención se relaciona además con composiciones y métodos para la selección, diagnóstico y desarrollo de terapias para trastornos relacionados con huesos tal como osteoporosis y fracturas de hueso. Los anticuerpos y fragmentos de anticuerpo dirigidos a la proteína Ror2 son particularmente útiles para originar la dimerización de las protéinas Ror2, conduciendo de esta manera la activación del Ror2.
CR10212A 2006-02-17 2008-08-18 Modulacion de la formacion osea CR10212A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77453406P 2006-02-17 2006-02-17
US84423906P 2006-09-13 2006-09-13

Publications (1)

Publication Number Publication Date
CR10212A true CR10212A (es) 2008-10-03

Family

ID=38437973

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10212A CR10212A (es) 2006-02-17 2008-08-18 Modulacion de la formacion osea

Country Status (19)

Country Link
US (1) US20090047287A1 (es)
EP (1) EP1984395A2 (es)
JP (1) JP2009527485A (es)
KR (1) KR20080095269A (es)
AR (1) AR060104A1 (es)
AU (1) AU2007217779A1 (es)
BR (1) BRPI0707864A2 (es)
CA (1) CA2638803A1 (es)
CR (1) CR10212A (es)
EC (1) ECSP088682A (es)
IL (1) IL193271A0 (es)
MX (1) MX2008010511A (es)
NO (1) NO20083497L (es)
PA (1) PA8715601A1 (es)
PE (1) PE20071309A1 (es)
RU (1) RU2008131052A (es)
SV (1) SV2009002997A (es)
TW (1) TW200800266A (es)
WO (1) WO2007098198A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079246A1 (en) * 2010-05-05 2013-03-28 Addex Pharma Sa Methods and Tools for Screening Agents Exhibiting an Activity on Receptors of the Tumor Necrosis Factor Receptor Superfamily
WO2013070033A1 (ko) * 2011-11-09 2013-05-16 주식회사 아이엠헬스케어 골다공증 및 골회전율 진단 스트립
KR101354826B1 (ko) * 2011-12-08 2014-01-27 아주대학교산학협력단 중간엽줄기세포 렙틴분비능을 이용한 골다공증 예방 또는 치료용 물질 스크리닝 방법
WO2013103637A1 (en) * 2012-01-03 2013-07-11 The Board Of Trustees Of The Leland Stanford Junior University Analysis and targeting of ror2 in cancer
JP6463029B2 (ja) * 2013-08-02 2019-01-30 有未 伊谷 ヒト間葉系幹細胞を特異的に認識するモノクローナル抗体並びにこれを用いたヒト間葉系幹細胞の分離及び/または品質評価を行う方法
SG11201610795VA (en) * 2014-08-01 2017-02-27 Purec Co Ltd Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method
JP7057557B2 (ja) * 2015-07-31 2022-04-20 国立大学法人大阪大学 上皮疾患に対する治療及び/又は予防有効性を評価する方法、上皮疾患治療剤のスクリーニング方法、及び上皮疾患治療剤
US11254742B2 (en) * 2016-05-13 2022-02-22 Bioatla, Inc. Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
GB201718985D0 (en) 2017-11-16 2018-01-03 Univ London Queen Mary Treatment
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization
CN115786252B (zh) * 2023-02-07 2023-05-05 赛德特生物制药有限公司 人脐带间充质干细胞成骨诱导分化培养基及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
WO2001068812A2 (en) * 2000-03-14 2001-09-20 Regeneron Pharmaceuticals, Inc. Methods of stimulating cartilage formation
WO2004073731A1 (en) * 2003-02-19 2004-09-02 Aziz Ghahary 14-3-3 protein for prevention and treatment of fibroproliferative disorders
JP2006524508A (ja) * 2003-04-16 2006-11-02 ワイス 骨関連の活性を調節する新規な方法

Also Published As

Publication number Publication date
WO2007098198A3 (en) 2008-03-13
ECSP088682A (es) 2008-09-29
AR060104A1 (es) 2008-05-28
RU2008131052A (ru) 2010-03-27
EP1984395A2 (en) 2008-10-29
WO2007098198A2 (en) 2007-08-30
IL193271A0 (en) 2011-08-01
KR20080095269A (ko) 2008-10-28
PA8715601A1 (es) 2008-11-19
JP2009527485A (ja) 2009-07-30
CA2638803A1 (en) 2007-08-30
SV2009002997A (es) 2009-04-17
BRPI0707864A2 (pt) 2011-05-10
TW200800266A (en) 2008-01-01
AU2007217779A1 (en) 2007-08-30
MX2008010511A (es) 2008-11-18
US20090047287A1 (en) 2009-02-19
NO20083497L (no) 2008-10-31
PE20071309A1 (es) 2008-02-13

Similar Documents

Publication Publication Date Title
CR10212A (es) Modulacion de la formacion osea
CY1119127T1 (el) Επιτοποι σκληροστινης
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
CY1123580T1 (el) Συντετμημενες πρωτεϊνες συγχωνευσης actriib-fc
EA200600038A1 (ru) Антитела, специфические в отношении склеростина, и способы увеличения минерализации кости
NO20083011L (no) Modulatorer av muskarine receptorer
DE60227974D1 (de) Diagnostische tests auf periostinbasis
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
CO6400232A2 (es) Proteína de enlace al receptores cgrp humano
ECSP045093A (es) Anticuerpos para cd40
ATE423565T1 (de) Verwendung von substanz p zur mobilisierung und proliferation mesenchymaler stammzellen und zur wundheilung
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
ATE489852T1 (de) Systeme mit wechselbaren hörnern zur herstellung von eingeschlossenen produkten
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
MX2009007688A (es) Gel de fibrina para liberacion controlada de tgp-beta y usos del mismo.
MX2009007284A (es) Cd200 y su receptor, cd200r, modulan la masa osea por medio de la diferenciacion de osteoclastos.
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
DK1608399T3 (da) Kompleks af sclerostin og noggin eller chordin og stoffer, som modulerer dannelsen af komplekset
DE602005003830D1 (de) Vorrichtung zur befestigung von knochenlappen nach einer kraniotomie
AR093620A1 (es) Anticuerpos bmp-6
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
NO20073369L (no) Modulatorer av muskarinreseptorer
ATE470478T1 (de) An ovarialkrebs beteiligtes protein
DK2084183T3 (da) Pegyleret PTH som PTH-receptormodulatorer og anvendelser deraf

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)